# US 12,594,258 B2 · Inhibitors of MHC-I Nef downmodulation for treating HIV

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,594,258 B2
- Document ID: US12594258B2
- Status: Granted
- Kind: B2
- Application number: 17/785,809
- Filed: 2020-12-16
- Published: 2023-03-23
- Granted: 2026-04-07
- Earliest claimed: 2019-12-16
- Assignees: The Regents of the University of Michigan
- Applicants: The Regents of the University of Michigan
- Inventors: David H. Sherman; Kathleen L. Collins; Andrew W. Robertson; Mark M. Painter
- Web page: https://patentgrep.com/patent/US12594258B2

## CPC

- A61K 31/366: having six-membered rings, e.g. delta-lactones
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 31/18: for HIV
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds that can inhibit MHC-I downmodulation, and treat HIV infection in a patient in need of treatment thereof.

## Claims

### Claim 1

A method of treating human immunodeficiency virus (HIV) infection in a patient in need thereof comprising administering to the patient a pharmaceutically-effective amount of a compound having a structure of Formula (I), or a pharmaceutically acceptable salt thereof:
wherein
or represents a direct bond;
R1 is H, C(O)R6, or a sugar moiety;
R2 is H or OH;
R3 is H, C(O)R7 or a sugar moiety;
each R4 is independently H or C1-6alkyl;
R5 is C1-6alkyl or C2-6alkenyl; and
R6 and R7 are each independently C1-6 alkyl.

### Claim 2 (depends on 1)

The method of claim 1, wherein the HIV infection is HIV-1 infection.

### Claim 3 (depends on 2)

The method of claim 2, wherein the HIV-1 infection is infection with HIV subtype A, B, C, D, F, G, H, J, K, L, or a recombination thereof.

### Claim 4 (depends on 1)

The method of claim 1, wherein treating HIV infection comprises reducing or eliminating an HIV reservoir in a host.

### Claim 5 (depends on 1)

The method of claim 1, wherein the compound has a structure of Formula (Ia) or (Ib):
wherein R5′ is C1-5alkyl or C2-5alkenyl and R6′ is C1-5alkyl.

### Claim 6 (depends on 5)

The method of claim 5, wherein R5′ is C2-5alkenyl and R6′ is H.

### Claim 7 (depends on 5)

The method of claim 5, wherein R5′ and R6′ are methyl.

### Claim 8 (depends on 1)

The method of claim 1, wherein R1 is H.

### Claim 9 (depends on 1)

The method of claim 1, wherein R2 is H.

### Claim 10 (depends on 1)

The method of claim 1, wherein R3 is a sugar.

### Claim 11 (depends on 1)

The method of claim 1, wherein R3 is a carbamoyl sugar.

### Claim 12 (depends on 11)

The method of claim 11, wherein R3 is

### Claim 13 (depends on 12)

The method of claim 12, wherein at least one R4 is C1-6alkyl.

### Claim 14 (depends on 13)

The method of claim 13, wherein at least one R4 is methyl.

### Claim 15 (depends on 14)

The method of claim 14, wherein each R4 is methyl.

### Claim 16 (depends on 12)

The method of claim 12, wherein each R4 is C1-6alkyl.

### Claim 17

A method of treating human immunodeficiency virus (HIV) infection comprising administering to a patient in need thereof a pharmaceutically-effective amount of a compound, or pharmaceutically acceptable salt thereof, having a structure as shown in Table A:
TABLE A
Compound
No.
Structure
A1
A2

### Claim 18 (depends on 17)

The method of claim 17, wherein the compound of Table A is in the form of a salt.